Published in J Clin Gastroenterol on January 01, 2014
Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat (2008) 1.82
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (2010) 1.79
Significance of hepatitis B viremia levels determined by a quantitative polymerase chain reaction assay in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection. Am J Gastroenterol (2003) 1.75
Common breast cancer susceptibility loci are associated with triple-negative breast cancer. Cancer Res (2011) 1.65
Risk of hepatocellular carcinoma and extrahepatic malignancies in primary biliary cirrhosis. Eur J Gastroenterol Hepatol (2008) 1.62
Immunosuppression and donor age with respect to severity of HCV recurrence after liver transplantation. Liver Transpl (2005) 1.58
Hypoxemic reperfusion after 120 mins of intestinal ischemia attenuates the histopathologic and inflammatory response. Crit Care Med (2004) 1.50
Current chemotherapeutic options for the treatment of advanced bladder cancer: a review. Urol Oncol (2010) 1.43
Survivin and glycodelin transcriptional activity in node-positive early breast cancer: mRNA expression of two key regulators of cell survival. Breast Cancer Res Treat (2006) 1.43
Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer (2008) 1.43
Hepatitis B e antigen-negative chronic hepatitis B: natural history and treatment. Semin Liver Dis (2006) 1.40
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes. BMC Cancer (2013) 1.32
Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis (2013) 1.28
Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm (2009) 1.26
The evolving role of leptin and adiponectin in chronic liver diseases. Am J Gastroenterol (2006) 1.23
Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol (2010) 1.23
Increasing frequency of gram-positive cocci and gram-negative multidrug-resistant bacteria in spontaneous bacterial peritonitis. Liver Int (2013) 1.21
Risk factors for recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl (2008) 1.14
Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res (2009) 1.12
Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel. PLoS One (2012) 1.12
Pseudohyperkalemia in serum: the phenomenon and its clinical magnitude. J Lab Clin Med (2006) 1.12
Multifocal extranodal non-hodgkin lymphoma: a clinicopathologic study of 37 cases in Greece, a Hellenic Cooperative Oncology Group study. Oncologist (2005) 1.07
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat (2011) 1.05
Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer (2006) 1.04
Correlation of molecular human leukocyte antigen typing and outcome in high-risk melanoma patients receiving adjuvant interferon. Cancer (2010) 1.02
Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. Am J Hypertens (2010) 1.01
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat (2012) 1.01
Increasing frequency of Gram-positive bacteria in spontaneous bacterial peritonitis. Liver Int (2005) 0.99
Clinicopathologic significance of EGFR and Her-2/neu in colorectal adenocarcinomas. Cancer J (2006) 0.98
Serum adipokine levels in chronic liver diseases: association of resistin levels with fibrosis severity. Scand J Gastroenterol (2008) 0.98
Treatment of HBeAg-negative chronic hepatitis B. Semin Liver Dis (2003) 0.97
Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Breast Cancer Res Treat (2006) 0.97
Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat (2005) 0.95
Late complications of chemotherapy in testicular cancer. Cancer Treat Rev (2010) 0.95
Prognostic utility of β-tubulin isotype III and correlations with other molecular and clinicopathological variables in patients with early breast cancer: a translational Hellenic Cooperative Oncology Group (HeCOG) study. Breast Cancer Res Treat (2011) 0.94
Primary aortojejunal fistula due to foreign body: a rare cause of gastrointestinal bleeding. Eur J Gastroenterol Hepatol (2002) 0.94
Aspartate aminotransferase to platelet ratio index for fibrosis evaluation in chronic viral hepatitis. Eur J Gastroenterol Hepatol (2006) 0.94
Current treatment indications and strategies in chronic hepatitis B virus infection. World J Gastroenterol (2008) 0.93
EASL clinical practice guidelines on the management of chronic hepatitis B: the need for liver biopsy. J Hepatol (2009) 0.93
EGFR gene gain and PTEN protein expression are favorable prognostic factors in patients with KRAS wild-type metastatic colorectal cancer treated with cetuximab. J Cancer Res Clin Oncol (2014) 0.92
Combination treatment with metronomic temozolomide, bevacizumab and long-acting octreotide for malignant neuroendocrine tumours. Endocr Relat Cancer (2012) 0.92
Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver Int (2010) 0.91
Improved outcome of high-risk early HER2 positive breast cancer with high CXCL13-CXCR5 messenger RNA expression. Clin Breast Cancer (2012) 0.91
Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. Am J Gastroenterol (2007) 0.91
Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group. Clin Breast Cancer (2010) 0.91
Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev (2011) 0.91
Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J Thorac Oncol (2007) 0.91
Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. Crit Rev Oncol Hematol (2008) 0.90
Insulin resistance and metabolic syndrome in chronic liver diseases: old entities with new implications. Scand J Gastroenterol (2009) 0.90
The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of high-risk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial. Breast Cancer Res (2012) 0.89
Epithelial ovarian cancer: focus on targeted therapy. Crit Rev Oncol Hematol (2010) 0.89
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Res (2011) 0.89
Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review. Cancer Treat Rev (2011) 0.89
Primary hepatic actinomycosis. Am J Med Sci (2010) 0.89
HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. J Transl Med (2012) 0.89
Developments in the systemic treatment of metastatic cervical cancer. Cancer Treat Rev (2012) 0.87
Current progress in the treatment of chronic hepatitis C. World J Gastroenterol (2012) 0.87
Hepatitis B surface antigen: relation to hepatitis B replication parameters in HBeAg-negative chronic hepatitis B. J Hepatol (2010) 0.87
The expression of matrix metalloproteinases-2 and -9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res (2008) 0.87
XELOX versus FOLFOX6 as an adjuvant treatment in colorectal cancer: an economic analysis. Curr Med Res Opin (2009) 0.86
Serum HBV-DNA levels in inactive hepatitis B virus carriers. Gastroenterology (2002) 0.86
Smoking is associated with steatosis and severe fibrosis in chronic hepatitis C but not B. Scand J Gastroenterol (2009) 0.86
Circulating and liver tissue levels of retinol-binding protein-4 in non-alcoholic fatty liver disease. Hepatol Res (2009) 0.85
Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer (2014) 0.85
Long-term adefovir plus lamivudine therapy does not decrease creatinine clearance in HBeAg-negative chronic hepatitis B patients. Liver Int (2011) 0.85
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat (2005) 0.85
Morphometric microvascular characteristics in the prognosis of pancreatic and ampullary carcinoma. Pancreas (2007) 0.85
Post-operative combined radiation and chemotherapy with temozolomide and irinotecan in patients with high-grade astrocytic tumors. A phase II study with biomarker evaluation. Anticancer Res (2007) 0.85
Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation. Transplantation (2003) 0.85
Pericarditis and possible antiphospholipid syndrome on primary biliary cirrhosis. Ann Hepatol (2005) 0.84
Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology Group. Anticancer Res (2008) 0.84
Intramedullary spinal cord metastases in breast cancer: report of four cases and review of the literature. J Neurooncol (2005) 0.84
Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer. PLoS One (2013) 0.83
Diastolic myocardial dysfunction does not affect survival in patients with cirrhosis. Transpl Int (2012) 0.83
Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int (2013) 0.83
Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel. Anticancer Res (2012) 0.83
Her-2 protein expression, cellular localization, and gene amplification in colorectal carcinoma. Appl Immunohistochem Mol Morphol (2007) 0.83
Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. Anticancer Res (2005) 0.83
Peginterferon-alpha2a (40 kDa) for chronic hepatitis C. Expert Opin Pharmacother (2003) 0.83
Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patients. Anticancer Res (2008) 0.83
Hepatic progenitor cells in chronic hepatitis C: a phenomenon of older age and advanced liver disease. Virchows Arch (2010) 0.83
Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra). Int J Cardiol (2012) 0.82
Multiplex RT-PCR-based detections of CEA, CK20 and EGFR in colorectal cancer patients. World J Gastroenterol (2010) 0.82
Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection. Expert Rev Anti Infect Ther (2004) 0.82
Hepatoid pancoast tumor. A case report and review of the literature. Lung Cancer (2012) 0.81
Tolerability of adjuvant high-dose interferon alfa-2b: 1 month versus 1 year--a Hellenic Cooperative Oncology Group study. Anticancer Res (2004) 0.81
Myelotoxicity of oral topotecan in relation to treatment duration and dosage: a phase I study. Anticancer Drugs (2010) 0.81
Evaluation of the prognostic and predictive value of HER-1/EGFR in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Oncology (2008) 0.81
Ursodeoxycholic acid and histological progression in primary biliary cirrhosis. J Hepatol (2003) 0.81
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PLoS One (2013) 0.81
Danoprevir, a small-molecule NS3/4A protease inhibitor for the potential oral treatment of HCV infection. Curr Opin Investig Drugs (2010) 0.81
Precore mutant chronic hepatitis B - approach to management. MedGenMed (2003) 0.81